FibroGen(FGEN) - 2025 Q1 - Quarterly Results

Financial Performance - Total revenue from continuing operations for Q1 2025 was $2.7 million, a decrease of 89.3% compared to $25.4 million in Q1 2024[16] - Net loss from continuing operations for Q1 2025 was $16.8 million, or $0.16 per share, compared to a net loss of $49.0 million, or $0.49 per share, in the same period last year[16] - Total operating costs and expenses for Q1 2025 were $17.7 million, down from $74.5 million in Q1 2024[20] - The company reported a net income of $4.6 million from discontinued operations in Q1 2025, compared to a net loss of $32.9 million in the same period last year[20] Strategic Transactions - The sale of FibroGen China to AstraZeneca is expected to total approximately $185 million, with net cash held in China at closing estimated to be around $100 million[6] - Upon closing of the sale of FibroGen China, the company's cash runway is extended into the second half of 2027[6] Clinical Development - The initiation of the Phase 2 monotherapy trial of FG-3246 in mCRPC is anticipated in Q3 2025[6] - Topline results from the Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide are expected in Q4 2025[6] - A Type-C meeting request has been filed with the FDA for roxadustat in the treatment of anemia associated with LR-MDS, with feedback expected in Q3 2025[8] Cash Position - Cash, cash equivalents, and accounts receivable totaled $128.4 million as of March 31, 2025[16]